MX352959B - Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina. - Google Patents

Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.

Info

Publication number
MX352959B
MX352959B MX2014001873A MX2014001873A MX352959B MX 352959 B MX352959 B MX 352959B MX 2014001873 A MX2014001873 A MX 2014001873A MX 2014001873 A MX2014001873 A MX 2014001873A MX 352959 B MX352959 B MX 352959B
Authority
MX
Mexico
Prior art keywords
buprenorphine
delivery
abuse
mucoadhesive devices
resistant
Prior art date
Application number
MX2014001873A
Other languages
English (en)
Other versions
MX2014001873A (es
Inventor
Finn Andrew
Vasisht Niraj
Original Assignee
Biodelivery Sciences Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47712819&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX352959(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biodelivery Sciences Int Inc filed Critical Biodelivery Sciences Int Inc
Publication of MX2014001873A publication Critical patent/MX2014001873A/es
Publication of MX352959B publication Critical patent/MX352959B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención provee dispositivos mucoadhesivos que disuaden el abuso para el suministro de buprenorfina. Cada dispositivo comprende una capa mucoadhesiva y una capa de refuerzo y se selecciona el pH en cada capa, de manera aumenta al máximo la absorción de buprenorfina.
MX2014001873A 2011-08-18 2012-08-20 Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina. MX352959B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525094P 2011-08-18 2011-08-18
PCT/US2012/051618 WO2013026064A1 (en) 2011-08-18 2012-08-20 Abuse-resistant mucoadhesive devices for delivery of buprenorphine

Publications (2)

Publication Number Publication Date
MX2014001873A MX2014001873A (es) 2014-05-30
MX352959B true MX352959B (es) 2017-12-15

Family

ID=47712819

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001873A MX352959B (es) 2011-08-18 2012-08-20 Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.

Country Status (15)

Country Link
US (12) US8703177B2 (es)
EP (1) EP2744572B1 (es)
JP (5) JP6158810B2 (es)
KR (1) KR101944367B1 (es)
CN (2) CN103889508B (es)
AU (4) AU2012296346A1 (es)
BR (1) BR112014003651B1 (es)
CA (2) CA2845634C (es)
EA (2) EA201991223A1 (es)
ES (1) ES2660116T3 (es)
HK (1) HK1198958A1 (es)
IL (1) IL230996B (es)
MX (1) MX352959B (es)
SG (2) SG10201610097WA (es)
WO (1) WO2013026064A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577390T3 (es) * 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
CA2845634C (en) * 2011-08-18 2021-07-13 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
EP3148981A4 (en) * 2014-05-30 2017-11-08 The Trustees of Columbia University in the City of New York Multivalent ras binding compounds
US20160144528A1 (en) 2014-11-25 2016-05-26 Biodelivery Sciences International, Inc. Patch devices, methods and apparatus for forming, and testing pharmaceutical agent delivery patch devices
WO2016105563A1 (en) * 2014-12-23 2016-06-30 Arx, Llc Method of producing uniform buprenorphine-containing formulations
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
JP7143222B2 (ja) 2016-05-09 2022-09-28 ライフボンド リミテッド メッシュベースのインサイチュ架橋性組成物
WO2017196445A1 (en) * 2016-05-11 2017-11-16 Relmada Therapeutics, Inc. Abrasion-resistant opioid formulations
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3755310A4 (en) * 2018-02-22 2021-05-19 Avior, Inc. TRANSMUCOSAL FILM COMPOSITION AND METHOD OF MANUFACTURING AND USING THEREOF
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
US11318107B2 (en) 2019-02-22 2022-05-03 Avior, Inc. Pharmaceutical active-containing film delivery device for oral transmucosal administration
US11793980B2 (en) 2019-08-31 2023-10-24 Celero Systems, Inc. Intestinal attachment device
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981372A (en) 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US3640741A (en) 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2042888B (en) 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4285934A (en) 1979-07-13 1981-08-25 Tinnell James E Treatment for herpes virus
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4381296A (en) 1980-06-23 1983-04-26 Tinnell James E Treatment for herpes virus
JPS5758615A (en) 1980-09-26 1982-04-08 Nippon Soda Co Ltd Film agnent and its preparation
JPS5770816A (en) 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS57110254A (en) 1980-12-29 1982-07-09 Teijin Ltd Coating agent of injured membrane part of oral cavity
CH653550A5 (de) 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
US4518721A (en) 1982-03-26 1985-05-21 Richardson-Vicks Inc. Hydrophilic denture adhesive
JPS5948409A (ja) 1982-09-10 1984-03-19 Teikoku Seiyaku Kk 矯正的歯牙移動促進剤
CA1208558A (en) 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
JPS604120A (ja) 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4713246A (en) 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
EP0159604B1 (en) 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
EP0186019B1 (de) 1984-12-22 1993-10-06 Schwarz Pharma Ag Wirkstoffpflaster
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
JPS61280423A (ja) 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
GB8521494D0 (en) 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
JPH0729915B2 (ja) 1986-02-01 1995-04-05 帝國製薬株式会社 シ−ト状口腔内貼付剤
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
CH668187A5 (de) 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
JPH0794384B2 (ja) 1986-09-01 1995-10-11 帝国製薬株式会社 徐放性口腔内用製剤
US5196202A (en) 1986-09-01 1993-03-23 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form
US4906463A (en) 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
JPH0744940B2 (ja) 1986-12-24 1995-05-17 ライオン株式会社 口腔貼付用基材
DE3714074A1 (de) 1987-04-28 1988-11-10 Hoechst Ag Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage
US4867970A (en) 1987-05-21 1989-09-19 E. R. Squibb & Sons, Inc. Moistureless oral drug delivery formulation and method for preparing same
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5059189A (en) 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US4990339A (en) 1987-11-16 1991-02-05 H. B. Fuller Company Dermal treatment film
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5081157A (en) 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US5081158A (en) 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
JPH0645536B2 (ja) 1989-01-31 1994-06-15 日東電工株式会社 口腔粘膜貼付剤および口腔粘膜貼付製剤
JP2656338B2 (ja) 1989-01-31 1997-09-24 日東電工株式会社 口腔粘膜貼付製剤
US5750136A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
JP2839164B2 (ja) 1989-12-25 1998-12-16 帝國製薬株式会社 消炎鎮痛貼付剤
US5298258A (en) 1989-12-28 1994-03-29 Nitto Denko Corporation Acrylic oily gel bioadhesive material and acrylic oily gel preparation
US5332576A (en) 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5254345A (en) 1991-10-11 1993-10-19 Merck & Co., Inc. Poly(orthocarbonate acetal) bioerodible polymers
GB2273044B (en) 1992-12-02 1997-04-09 Pacific Chem Co Ltd Medicinal patches for percutaneous administration
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
DE69422925T2 (de) 1993-07-09 2000-08-17 Cygnus Therapeutic Systems Verfahren und vorrichtung für die transdermale oder transbuccale therapeutische verabreichung von nikotinsubstituten
JPH09504810A (ja) 1993-08-19 1997-05-13 シグナス，インコーポレイテッド 水溶性感圧粘膜接着剤
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
FR2712807B1 (fr) 1993-11-24 1996-02-23 Vetoquinol Sa Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
DE4341442C2 (de) 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
US5466465A (en) 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
US5679714A (en) 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
AU2703795A (en) 1994-06-23 1996-01-19 Procter & Gamble Company, The Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
DE69625549T2 (de) 1995-06-27 2003-05-15 Kao Corp Pflaster mit wasserlöslicher Klebeschicht
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
JP2791317B2 (ja) 1995-12-26 1998-08-27 株式会社三和化学研究所 多層フィルム製剤
FR2742989B1 (fr) 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
ES2252865T3 (es) 1997-09-26 2006-05-16 Noven Pharmaceuticals, Inc. Composiciones bioadhesivas y metodos para la administracion topica de agentes activos.
US20050048102A1 (en) 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
EP1079813B1 (en) 1998-04-29 2005-02-09 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
AU3470600A (en) 1999-01-14 2000-08-01 David Houze Compositions and methods for drug delivery
US20030170195A1 (en) 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
DE19960154A1 (de) 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
US20030124176A1 (en) 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20050074487A1 (en) 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US20030104041A1 (en) 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
BR0108379A (pt) 2000-02-08 2002-11-05 Euro Celtique Sa Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US6969374B2 (en) 2001-02-09 2005-11-29 Hager & Werken Gmbh & Co. Kg Injection syringe and disposal container for injection needle units
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
SI2316439T1 (sl) 2001-05-01 2015-10-30 Euro-Celtique S.A. Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid
CA2778114A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20030194420A1 (en) 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
EP1515674A4 (en) 2002-05-13 2008-04-09 Endo Pharmaceuticals Inc AGAINST MISUSE PROTECTED SOLID OPIOID DOSAGE FORM
KR20110120358A (ko) 2002-06-10 2011-11-03 유로-셀티크 소시에떼 아노뉨 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
DE60326354D1 (de) 2002-08-20 2009-04-09 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
MXPA05004578A (es) 2002-10-31 2005-07-26 Umd Inc Composicion terapeutica para el suministro de drogas a y a traves de epitelios de proteccion.
US20050013845A1 (en) 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
NZ539936A (en) 2002-12-13 2007-06-29 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia
US20040191301A1 (en) 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
US20040213828A1 (en) 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
US20040219195A1 (en) 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
MY141815A (en) 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
GEP20084561B (en) 2003-10-28 2008-12-10 Noven Pharma System and method for controlled drug release and transdermal drug delivery device
JP2007527415A (ja) 2003-10-30 2007-09-27 アルザ・コーポレーシヨン 乱用の可能性が低い経皮鎮痛剤システム
WO2005055981A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
LT2351555T (lt) 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
EP1584335A3 (en) 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
AU2005286733B2 (en) 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7827983B2 (en) 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
EP1968539A2 (en) * 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
ES2577390T3 (es) * 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
WO2008036980A1 (en) * 2006-09-22 2008-03-27 Alltranz Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
US20090270438A1 (en) 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
JP2010518086A (ja) * 2007-02-09 2010-05-27 デュレクト コーポレーション スフェンタニルおよびナロキソンを含む経口腔投与製剤
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
CA2728912C (en) 2008-06-23 2018-04-10 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CA2845634C (en) * 2011-08-18 2021-07-13 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine

Also Published As

Publication number Publication date
IL230996A0 (en) 2014-03-31
CA3119258A1 (en) 2013-02-21
KR101944367B1 (ko) 2019-01-31
CN103889508A (zh) 2014-06-25
AU2021201650A1 (en) 2021-04-08
SG11201401446RA (en) 2014-09-26
AU2018200402B2 (en) 2019-04-18
JP6657454B2 (ja) 2020-03-04
ES2660116T3 (es) 2018-03-20
JP2014521753A (ja) 2014-08-28
US20240108615A1 (en) 2024-04-04
KR20140059240A (ko) 2014-05-15
JP2022058678A (ja) 2022-04-12
US20150246002A1 (en) 2015-09-03
US20160324849A1 (en) 2016-11-10
US20160095821A1 (en) 2016-04-07
AU2018200402A1 (en) 2018-02-08
US8703177B2 (en) 2014-04-22
EA033256B1 (ru) 2019-09-30
WO2013026064A1 (en) 2013-02-21
BR112014003651A2 (pt) 2017-03-21
CA2845634C (en) 2021-07-13
US20130045268A1 (en) 2013-02-21
US20220016109A1 (en) 2022-01-20
US20180064706A1 (en) 2018-03-08
EP2744572A4 (en) 2015-06-03
CN107441067A (zh) 2017-12-08
JP6158810B2 (ja) 2017-07-05
EP2744572B1 (en) 2017-12-13
US20200129503A1 (en) 2020-04-30
SG10201610097WA (en) 2017-01-27
JP2019108362A (ja) 2019-07-04
AU2012296346A1 (en) 2014-04-03
BR112014003651B1 (pt) 2022-03-29
AU2019206022A1 (en) 2019-08-01
JP2020079277A (ja) 2020-05-28
JP2017193563A (ja) 2017-10-26
MX2014001873A (es) 2014-05-30
HK1198958A1 (en) 2015-06-19
CN103889508B (zh) 2017-09-12
US20190240214A1 (en) 2019-08-08
IL230996B (en) 2019-02-28
US20240165102A1 (en) 2024-05-23
EP2744572A1 (en) 2014-06-25
CA2845634A1 (en) 2013-02-21
US20160339016A1 (en) 2016-11-24
US20190000833A1 (en) 2019-01-03
EA201991223A1 (ru) 2019-10-31
EA201490425A1 (ru) 2014-07-30
NZ622610A (en) 2016-05-27

Similar Documents

Publication Publication Date Title
MX352959B (es) Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
HK1203048A1 (en) Transdermal delivery system comprising buprenorphine
SG10201606827RA (en) Polishing agent, polishing agent set, and substrate polishing method
GB2505601B (en) Credential authentication methods and systems
EP2718886A4 (en) APPARATUSES, METHODS AND SYSTEMS FOR SEGMENTATION IN PAYMENT CONFIDENTIALITY UNITS
EP2761311A4 (en) AUTHENTICATION SYSTEMS AND METHODS
EP2709522A4 (en) SYSTEMS, APPARATUSES, DEVICES, AND METHODS FOR NEUROPHYSIOLOGICAL REHABILITATION AND / OR SYNERGIC FUNCTIONAL DEVELOPMENT
PL3020730T3 (pl) Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych
EP2724309A4 (en) DEVICES, METHODS AND SYSTEMS FOR A PLATFORM FOR PAIRING SOCIAL DATA
EP2755614A4 (en) SYSTEMS AND METHOD FOR PROSTATE TREATMENT
ZA201403548B (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
EP2925489A4 (en) Smooth diamond surfaces and cmp method for forming
EP2737112A4 (en) DIAMOND SEMICONDUCTOR SYSTEM AND METHOD THEREOF
HK1178341A1 (zh) 生成安全裝置密鑰
EP2785799A4 (en) COATED COLOR CHANGING PARTICLES AND DEVICES AND SYSTEMS THEREFOR AND METHOD THEREFOR
HK1184806A1 (zh) 塗覆材料、塗覆材料層、以及積層結構體
ZA201305697B (en) Liposome formulation suitable for treating or preventing tuberculosis
EP2729818A4 (en) DEVICES, METHODS AND SYSTEMS FOR DETERMINING A FORMING PROPERTY
EP2766451A4 (en) FOAM PROTECTIVE FIRE PROTECTION SYSTEMS AND METHOD THEREFOR
IL218584A0 (en) System and method for securing boip phone against surface eavesdropping
UA54014U (ru) Способ лечения больных хроническим некалькулезным холециститом в сочетании с ожирением
ES1075995Y (es) Dispositivo para la evacuacion de personas en edificios.
GB201105601D0 (en) Gomarquee.com online comparison for event and marquee organisations
AU2011902943A0 (en) Call authentication methods and systems
HK1172203A2 (en) Systems and methods for facilitating convenient teleconferencing between users located in different time zones

Legal Events

Date Code Title Description
FG Grant or registration